ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.

CANF Can Fite BioPharma Ltd

2,12
0,09 (4,43%)
04 Mai 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Can Fite BioPharma Ltd CANF AMEX Common Stock
  Änderung Änderung % Aktuell Zeit
0,09 4,43% 2,12 01:59:56
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
2,03 2,00 2,27 2,09 2,03
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
25.4.202413:00BWLong-term Complete Response to Can-Fite's Namodenoson in..
15.4.202413:00BWCan-Fite: Scientific Article Published by KOL Presents..
03.4.202413:00BWCan-Fite: Submits FDA with an IND Application to Conduct..
28.3.202412:00BWCan-Fite Reports 2023 Financial Results and Clinical Update
11.3.202412:27EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11.3.202412:00BWNamodenoson Treatment for Pancreatic and Liver Cancer: Data..
28.2.202413:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
28.2.202413:00BWCan-Fite Broadens its Strong Intellectual Property (IP) for..
14.2.202421:32EDGAR2Form SC 13G - Statement of acquisition of beneficial..
30.1.202413:24EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
30.1.202413:00BWCan-Fite Expands the Out-Licensing Deal with Ewopharma to..
29.1.202413:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29.1.202413:00BWCan-Fite: Top Scientific Journal Published Positive Data..
08.1.202406:15EDGAR2Form EFFECT - Notice of Effectiveness
28.12.202322:16EDGAR2Form F-3/A - Registration statement by foreign private..
20.12.202313:09EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20.12.202313:00BWThe Anti-Obesity Effect of Can-Fite’s Namodenoson: Molecular..
18.12.202313:07EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
18.12.202313:00BWCan-Fite Received FDA Positive Response to Psoriasis..
12.12.202322:15EDGAR2Form F-3 - Registration statement by foreign private issuers
04.12.202313:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04.12.202313:00BWCan-Fite’s Namodenoson for the Treatment of Pancreatic..
30.11.202313:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
30.11.202313:00BWCan-Fite Reports Third Quarter 2023 Financial Results and..
22.11.202322:20EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
22.11.202322:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21.11.202322:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21.11.202319:53GLOBECan-Fite Announces Exercise of Warrants for Approximately..
21.11.202313:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21.11.202313:00BWCan-Fite: Complete Response and 6.9 Years Overall Survival..
01.11.202312:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01.11.202312:00BWCan-Fite Issues Business Update: All Clinical Programs and..
30.10.202312:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
30.10.202312:00BWCan Fite: Namodenoson Inhibits Pancreatic Carcinoma..
26.10.202313:11EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
26.10.202313:00BWCan-Fite to Harness Artificial Intelligence to Develop Novel..
10.10.202313:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
09.10.202313:00BWCan-Fite to Share its Rare Genetic Disease Lowe Syndrome..
27.9.202313:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
27.9.202313:00BWCan-Fite Novel Approach for the Treatment of Pancreatic..
07.9.202313:25EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07.9.202313:00BWCan-Fite to Share with Investors Latest Oncology and Rare..
01.9.202322:16EDGAR2Form POS AM - Post-Effective amendments for registration..
01.9.202322:15EDGAR2Form F-3 - Registration statement by foreign private issuers
31.8.202313:12EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
31.8.202313:00BWCan-Fite Reports Second Quarter 2023 Financial Results &..
24.8.202313:19EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
24.8.202313:10BWCan-Fite Enters Rare Genetic Disease Field Based on..
18.8.202313:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
18.8.202313:00BWCan-Fite Submitted to FDA a Pediatric Plan to Allow..

Kürzlich von Ihnen besucht

Delayed Upgrade Clock